TY - JOUR T1 - Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and ischemic stroke, with focus on (co-)morbidity and aging / cellular senescence (SASKit): protocol for a prospective cohort study JF - medRxiv DO - 10.1101/2020.04.09.20037010 SP - 2020.04.09.20037010 AU - Larissa Henze AU - Uwe Walter AU - Hugo Murua Escobar AU - Christian Junghanß AU - Robert Jaster AU - Rüdiger Köhling AU - Falko Lange AU - Ali Salehzadeh-Yazdi AU - Olaf Wolkenhauer AU - Mohamed Hamed AU - Israel Barrantes AU - Daniel Palmer AU - Steffen Möller AU - Axel Kowald AU - Nicole Heussen AU - Georg Fuellen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20037010.abstract N2 - Aging-related processes such as cellular senescence are believed to underlie the accumulation of diseases in time, causing (co-)morbidity, including cancer, thromboembolism and stroke. Intervening into these processes may delay, stop or reverse morbidity. To study the link between (co-)morbidity and aging, by exploring biomarkers and molecular mechanisms of disease-triggered deterioration, we will recruit 50 patients with pancreatic ductal adenocarcinoma, 50 patients with (thromboembolic) ischemic stroke and 50 controls, at Rostock University Medical Center. We will gather routine blood data, clinical performance measurements and patient-reported outcomes at up to 9 points in time, and in-depth transcriptomics & proteomics at two early time points. Aiming for clinically relevant biomarkers, the primary outcome is a composite of probable sarcopenia, clinical performance (described by ECOG Performance Status for patients with pancreatic ductal adenocarcinoma and the Modified Rankin Scale for patients with stroke) and quality of life. Further outcomes cover other aspects of morbidity such as cognitive decline, and of comorbidity such as vascular or cancerous events. The data analysis is comprehensive in that it includes biostatistics & machine learning, both following standard role models & additional explorative approaches. Predictive biomarkers for interventions addressing senescence may become available if the biomarkers that we find are predominantly related to aging / cellular senescence. Similarly, diagnostic biomarkers will be explored for their relationship to aging / cellular senescence. Our findings will require validation in independent studies, and our dataset shall be useful to validate the findings of other studies. In some of the explorative analyses, we shall include insights from systems biology modeling as well as insights from preclinical animal models. We humbly suggest that our detailed study protocol and data analysis plan may also guide other biomarker exploration trials.In Brief The SASKit (“Senescence-Associated Systems diagnostics Kit for cancer and stroke”) study primarily aims to discover novel biomarkers for deterioration of health and (co-)morbidities triggered by pancreatic ductal adenocarcinoma or ischemic stroke.Competing Interest StatementDr. Walter reports personal fees from Ipsen Pharma, grants and personal fees from Merz Pharma, personal fees from Allergan, personal fees from Bristol-Myers Squibb, personal fees from Daiichi Sankyo, personal fees from Bayer Vital, personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees from Thieme, and personal fees from Elsevier Press, all outside the submitted work. The other authors have nothing to disclose.Clinical TrialGerman Clinical Trials Register (DRKS00021184)Funding StatementThe authors acknowledge the financial support by the Federal Ministry of Education and Research (BMBF) of Germany for the SASKit study (FKZ 01ZX1903A). The funder had no role in the design of the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/AAUCArea Under the CurveBMIBody Mass IndexCA19-9Carbohydrate AntigenCEACarcinoembryonic antigenCIConfidence intervalCRPC-reactive proteinECOGEastern Cooperative Oncology GroupHRHazard ratioINRInternational normalized ratioISIschemic StrokeLDHLactate dehydrogenaseNIHSSNIH-Stroke ScaleNYHANew York Heart AssociationPDACPancreatic Ductal AdenocarcinomaPSPerformance statusQoLQuality of LifeROCReceiver-Operator CharacteristicRSFRandom survival forestsSASKitSenescence-Associated Systems diagnostics Kit for cancer and strokeSASPSenescence Associated Secretory Phenotype ER -